Global $7.7 Bn Molecular Diagnostics Market 2018-2019 & 2024

DUBLIN, Feb. 13, 2019 /PRNewswire/ --

The "Global Molecular Diagnostics Market - Technologies, Products, Applications and End-Use Sectors" report has been added to ResearchAndMarkets.com's offering.

Global market for Molecular Diagnostics is dominated by Infectious Diseases, estimated at US$3.9 billion in 2018 and is anticipated to post a CAGR of 11.9% between 2018 and 2024 and reach a projected US$7.7 billion by 2024.

Emergence of novel next generation sequencing technologies, extensive use of next generation sequencing technologies in clinical diagnostics, application of sequencing technologies in cancer to detect mutations are some of the factors fueling the growth of sequencing technologies usage in the molecular diagnostics field. Growing prevalence of genetic disorders, rising demand for personalized medicine etc., are some of the factors attributed to the fastest growth nature of molecular diagnostics applications in Genetic testing.

Molecular Diagnostics technologies market explored in this report includes PCR Polymerase Chain Reaction (PCR), Sequencing, Hybridization and Others comprising Microarrays, Nanotechnology etc. The study includes the market analysis for Molecular Diagnostics product types - Reagents and Consumables, Instruments and Software & Services.

The study also explores the market analysis for Molecular Diagnostics End-Use sectors comprising Hospitals & Diagnostics Labs, Research Institutes & Universities and Others including Blood Banks, Nursing Homes, Local Public Health Laboratories, point of Care settings etc.

Research Findings & Coverage

• This most comprehensive report on Molecular Diagnostics, analyzes the global market with respect to technologies, product types, applications and end-use sectors
• Molecular Diagnostics' market size is estimated in this report by product types, technologies, applications and end-use sectors across all major countries
• Rapid and Early Confirmation of Dengue Using Molecular Diagnostics
• Creation of Novel and Powerful Adaptive PCR Technique for Rapid Genetic Analysis
• Emergence of CRISPR as a Novel Molecular Diagnostic Tool
• Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
• Major companies profiled - 48
• The industry guide includes the contact details for 169 companies

Key Topics Covered:

PART A: GLOBAL MARKET PERSPECTIVE

1. INTRODUCTION
1.1 Product Outline
1.1.1 Significance of Diagnostics
1.1.2 Molecular Diagnostics Defined
1.1.2.1 Molecules Detected Via Molecular Diagnostics
1.1.2.2 A Historic Review of Molecular Diagnostics
1.1.2.3 Basic Steps Involved in Molecular Diagnostics Assay
1.1.2.4 Sample Collection and Storage
1.1.2.5 Uses of Molecular Diagnostics
1.1.2.6 Technologies of Molecular Diagnostics
1.1.2.6.1 Polymerase Chain Reaction (PCR)
1.1.2.6.2 Sequencing
1.1.2.6.3 Hybridization
1.1.2.6.3.3 FISH
1.1.2.6.4 Immunohistochemistry
1.1.2.6.5 NAAT- Nucleic Acid Amplification Technologies
1.1.2.6.6 Microarray
1.1.2.6.7 Nanotechnology
1.1.2.7.1 Reagents and Consumables
1.1.2.7.2 Instruments
1.1.2.7.3 Software & Services
1.1.2.8 Applications of Molecular Diagnostics
1.1.2.8.1 Infectious Diseases
1.1.2.8.2 Oncology
1.1.2.8.3 Blood Testing
1.1.2.8.4 Genetic Testing
1.1.2.8.5 Prenatal Testing
1.1.2.8.5.1 Types of Prenatal Tests

• Chorionic villus sampling - (CVS)
• Aminocentesis

1.1.2.8.6 Agriculture Applications
1.1.2.8.7 Veterinary Application
1.1.2.8.8 Dairy Application
1.1.2.9 End-Use Applications of Molecular Diagnostics

2. KEY MARKET TRENDS
2.1 Silicon Based-Nanostructured Microfluidics - A Novel Molecular Diagnostic Technology for Fetal Aneuploidy
2.2 Rapid and Early Confirmation of Dengue Using Molecular Diagnostics
2.3 Imprinted NanoVelcro Microchips Featured to Isolate and Characterize Circulating Fetal Trophoblast
2.4 Creation of Novel and Powerful Adaptive PCR Technique for Rapid Genetic Analysis
2.5 Web Tool Foretells Phenotypes Using little DNA Sample
2.6 Emergence of CRISPR as a Novel Molecular Diagnostic Tool

3. KEY GLOBAL PLAYERS

• Abbott Diagnostics (United States)
• Agendia NV (The Netherlands)
• Agilent Technologies, Inc. (United States)
• Becton, Dickinson and Company (United States)
• Biomrieux SA (France)
• Bio-Rad Laboratories, Inc. (United States)
• Danaher Corporation (United States)
• DNA Diagnostics Center (United States)
• Elitechgroup (France)
• F. Hoffmann-La Roche Ag (Switzerland)
• GE Healthcare, Inc. (Untied States)
• Genmark Diagnostics, Inc. (United States)
• Genomic Health, Inc. (United States)
• Grifols International, S.A. (Spain)
• Hologic, Inc. (United States)
• Illumina, Inc. (United States)
• Kaneka Eurogentec S.A. (Belgium)
• Laboratory Corporation of America Holdings (United States)
• Luminex Corporation (United States)
• Milliporesigma (United States)
• Myriad Genetics, Inc. (United States)
• Novartis AG (Switzerland)
• Origene Technologies, Inc. (United States)
• Ortho Clinical Diagnostics (United States)
• Oxford Gene Technology (United Kingdom)
• Perkinelmer Inc. (United States)
• Promega Corporation (United States)
• Qiagen N.V. (The Netherlands)
• Savyon Diagnostics (Israel)
• Seegene Inc. (South Korea)
• Siemens Healthcare GmbH (Germany)
• Sorenson Genomics, LLC (United States)
• Sysmex Inostics GmbH (Germany)
• Thermo Fisher Scientific Inc. (United States)
• Transgenomic Inc. (United States)
• Wuxi Nextcode (China)

4. KEY BUSINESS TRENDS

• Savyon Introduces Savvygen STI RT-PCR Assays for STI
• USDA Grants a Contract to Bio-Rad In View of Pathogen Detection
• Supply Contract Made by OncoDNA in Romania and Turkey
• Release of Novel Molecular Diagnostics Test for TB by BD
• Introduction of TruSightTM Oncology 500 by Illumina
• Adoption of EdgeSeq Technology of HTG in IOR's Genomics Hub
• Major Stakes of Hain Lifescience Taken Over by Bruker
• QIAGEN Join Forces with NeuMoDx to Provide NGS for Completely Incorporated MDx
• Chinese Launch of MammaPrint and BluePrint of Agendia In Association with Genecast
• Introduction of a Novel Real Time PCR Analysis Technology by Seegene
• Commercial Release of OncoBEAM EGFR Kit v2 (RUO) in Europe and Asia by Sysmex
• QIAGEN Extends Its Footprints In Africa By Collaborating With The Scientific Group
• Admera Signs a Partnership Deal with Quadrant
• Savyon is ready to Release Savvygen Lyophilized RT-PCR Assays for Stomach Flu
• Rapid DNA Analyis Technology Offered by Thermo Fisher for Reassembling
• Release of Ion AmpliSeq HD Technology by Thermo Fisher
• Introduction of QIAseq 16S Panels and UCP Multiplex PCR kit by QIAGEN for Microbiome Profiling
• Release of Novel Probes for In Situ Hybridization Protocols
• Initiation of Clinical Studies of VERIGENE II Gastrointestinal Assay by Luminex
• MammaPrint and BluePrint of Agendia are Now Accessible in SouthEast Asia Via Angsana
• Unicancer Adopts MammaPrint and BluePrint of Agendia in France
• Expansion of Real-Time PCR assay Collection by R-Biopharm and ELITechGroup
• Roche, DIAN and Foundation Medicine Join Forces to Enhance Chinese Tailored Cancer care
• Expansion of In Situ Hybridization Probes Panel for Clinical Access by Agilent
• Natera Join Forces with QIAGEN to Design Advanced Genetic Testing Assays
• Introduction of Novel CE marked Assay by QIAGEN to Detect Trichomonas
• Introduction of ccfDNA Blood Collection Tube by BD
• Commercial Release of Oncotype DX AR-V7 Nucleus Detect Test by Genomic Health
• QIAGEN to Take Over STAT-Dx
• Illumina Join Forces with KingMed to Design NGS Technology for CFDA Clearance
• World's Foremost Multiplex MDx Assay Designed by Seegene
• Launch of Novel Salmonella Multiplex PCR Solution by Thermo Fisher
• Agendia Alliance with Bluebee for Commercial Release of NGS-Based MammaPrint BluePrint
• Co validation of MammaPrint BluePrint By Agendia and UZ Leuven Before EU Release
• Agendia Alliances with Institut Curie to Co Validate MammaPrint BluePrint Breast Cancer kit
• Release of NetSeqTM 550Dx System by Illumina
• Extension of Respiratory Disease Panel by Cepheid
• Launch of Custom Solutions Business by QIAGEN to Assist MDx and Life Science Firms
• AutoGenomics Partners With LCM for Precision Medicine
• Admera Extends its Existence in Asia through 3 Alliances
• Release of riskScoreTM by Myriad to Detect Hereditary Cancer
• Luminex and Sutter Join Forces To Offer Multiple Luminex Diagnostic Systems
• Savyon Launches Multiplex Lyophilized RT-PCR Assays for Respiratory illness
• HomeDNATM Now Accessible Throughout the Nation
• Helix Collaborates With Admera to Offer Genetic Tests For Cardiology Related Ailments
• European Launch of Real-Time PCR System for Clinical Diagnostics by Agilent
• Agendia Collaborates With Agilent for Molecular Cancer Diagnostics
• European Release of cobas MRSA/SA test By Roche
• Release of HTG EdgeSeq PATH Assay By HTG
• Admera Alliances with University of Rochester to Evaluate Pharmacogenomics
• Thermo Fisher and Seegene Partners to File for U.S FDA Clearance
• Launch of Second Generation Real Time PCR Technology by Seegene
• Instituto Valenciano de Oncologa and HTG Partner to Assess Breast Cancer reappearance Risk
• Launch of GenetiSure Dx Postnatal Assay By Agilent To Detect Genetic Anomalies
• Multiplicom Completely Taken Over by Agilent
• Seegene Unveils a Novel Normalization Software Technology for MDx
• Adoption of ICE COLD-PCR of Transgenomic by LifeLabs
• NAT Donor Screening Unit of Hologic Taken Over by Grifols
• Introduction of CALR mutation assay for MPN Diagnosis by QIAGEN
• Extension of Supply Contract between Merck and Roche
• Launch of Novel Targetted NGS Panel by OGT to Evaluate HF Related SNV and CNV
• Cepheid Taken Over by Danaher
• MammaPrint of Agendia is Now Accessible in Middle East Through Cryogene
• Release of TruSight Tumor 170 by Illumina
• Seegene Signs a Global Alliance with Hologic for Multiplex Molecular Diagnostic Assay
• Xpert Xpress Flu/RSV Now Accessible in EU and Nations Recognizing CE Mark
• Agendia Extends its Footprints in Germany
• A Chinese and Indian Distribution Deal Signed by Transgenomic for ICEme Kits
• Refurbishment of PGxOne Plus by Admera
• Burning Rock and Agilent Collaborates on Molecular Diagnostics
• Sequenom Completely Taken Over by LabCorp
• Commercialization of Seegene's Diagnostics Kits in Italy
• Transgenomic Partners with VWR for the Distribution of ICEme Kit
• Expansion of MDx Portfolio of Rosetta by Adding OncoGxSelect
• Release of In Silico -Derived Multiplex Real-Time PCR Assays by Seegene
• Commercial Release of Novel CLIA Assay by Transgenomic to Detect Mutations in EGFR C7975
• Release of "Digital NGS" solutions by QIAGEN against Genetic Variation

5. GLOBAL MARKET OVERVIEW
5.1 Global Molecular Diagnostics Market Overview by Technology
5.1.1 Molecular Diagnostics Technologies Market Overview by Global Region
5.1.1.1 PCR
5.1.1.2 Sequencing
5.1.1.3 Hybridization
5.1.1.4 Other Technologies
5.2 Global Molecular Diagnostics Market Overview by Product Type
5.2.1 Molecular Diagnostics Products Market Overview by Global Region
5.2.1.1 Reagents & Consumables
5.2.1.2 Instruments
5.2.1.3 Software & Services
5.3 Global Molecular Diagnostics Market Overview by Application
5.3.1 Molecular Diagnostics Applications Market Overview by Global Region
5.3.1.1 Infectious Diseases
5.3.1.2 Oncology
5.3.1.3 Blood Testing
5.3.1.4 Genetic Testing
5.3.1.5 Prenatal Testing
5.3.1.6 Other Applications
5.4 Global Molecular Diagnostics Market Overview by End-Use Sector
5.4.1 Molecular Diagnostics End User Market Overview by Global Region
5.4.1.1 Hospitals & Diagnostics Labs
5.4.1.2 Research Institutes & Universities
5.4.1.3 Other End-Use Sectors

PART B: REGIONAL MARKET PERSPECTIVE

REGIONAL MARKET OVERVIEW

6. NORTH AMERICA

Major Market Players

• Abbott Diagnostics (United States)
• Admera Health (United States)
• Agilent Technologies, Inc. (United States)
• Autogenomics, Inc. (United States)
• Becton, Dickinson and Company (United States)
• Bio-Rad Laboratories, Inc. (United States)
• Danaher Corporation (United States)
• Beckman coulter, Inc. (United States)
• Cepheid (United States)
• DNA diagnostics center (United States)
• Exact Sciences Corporation (United States)
• Foundation medicine (United States)
• GE Healthcare (United States)
• GenMark Diagnostics, Inc. (United States)
• Genomic Health, Inc. (United States)
• Hologic, Inc. (United States)
• HTG Molecular Diagnostics, Inc. (United States)
• Illumina, Inc. (United States)
• Laboratory Corporation of America Holdings (United States)
• Luminex Corporation (United States)
• MilliporeSigma (United States)
• Myriad Genetics, Inc. (United States)
• OriGene Technologies (United States)
• Ortho Clinical Diagnostics (United States)
• Pathogenetix, Inc. (United States)
• PerkinElmer, Inc. (United States)
• Promega Corporation (United States)
• Sorenson Genomics, Inc. (United States)
• Thermo Fisher Scientific, Inc. (United States)
• Transgenomic, Inc. (United States)
  

7. EUROPE

Major Market Players

• Agendia NV (The Netherlands)
• Analytik Jena (Germany)
• BioMerieux SA (France)
• ELITechGroup (France)
• F. Hoffmann-La Roche AG (Switzerland)
• Grifols International S.A (Spain)
• Kaneka Eurogentec S.A (Belgium)
• Novartis International AG (Switzerland)
• Oxford Gene Technology (The United Kingdom)
• QIAGEN N.V. (The Netherlands)
• Siemens Healthcare GmbH (Germany)
• Sysmex Inostics GmbH (Germany)

8. ASIA-PACIFIC

Major Market Players

• BGI-Shenzhen (China)
• Dian Diagnostics Group Co., Ltd. (China)
• Seegene, Inc. (South Korea)
• Shanghai Runda Medical Technology Co., Ltd. (China)
• WuXi NextCODE (China)

For more information about this report visit https://www.researchandmarkets.com/research/vh6hbx/global_7_7_bn?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com